Eli Lilly (LLY) Slid on Rare Revenue Miss in its 3Q Update
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
24/7 Wall St. on MSN16h
2 Stocks That Could Split Very Soon
Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
MGC: A High Bar For This Mega-Cap Fund
The Vanguard Mega Cap ETF is outperforming the S&P 500 but lagging peers like XLG and OEF. Read more on the analysis of MGC ...
Here's why Ozempic maker's new weight-loss drug isn't good enough for investors
Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...
7 Best Weight Loss Drug Stocks to Buy in 2025
The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...
Ozempic parent's new weight-loss drug works better, but not quite good enough
CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...
Why Eli Lilly Stock Flopped Today
Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...